A single intravenous dose of MRG-110, an anti-microRNA drug, significantly reduced miR-92a levels from the blood of healthy humans.

<span style="color: #ff6600;"><a style="color: #ff6600;" href="https://home.liebertpub.com/news/first-in-human-study-with-novel-antisense-oligonucleotide/3743">"According to documented, promising therapeutic possible, locked nucleic acid (LNA)-based anti-miR-92a was further developed and tested in a first in human analysis," said Stefanie Dimmeler, PhD, Goethe University, Frankfurt, Germany and coauthors. "MRG-110 caused de-repression of gene goals in human peripheral blood cells"</a></span>

<em>This is an important randomized, double-blind, placebo-controlled, dose-escalating study translating previous work on systemically delivered LNA-modified anti-miR oligonucleotide compounds to efficiently lower miR-92a levels in human peripheral blood,"-</em>Graham C. Parker, PhD, Executive Editor, The Carman and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Children's Hospital of Michigan, Detroit, MI
<div class="content-src-label"><strong>Source:</strong></div>
<div class="content-src-value">

<span style="color: #ff6600;"><a style="color: #ff6600;" href="https://home.liebertpub.com/news/first-in-human-study-with-novel-antisense-oligonucleotide/3743" target="_blank" rel="noopener noreferrer"><span class="DICOrgLink">Mary Ann Liebert, Inc., Publishers</span></a></span>

</div>
<div class="content-src-label"><strong>Journal reference:</strong></div>
<div class="content-src-value">

Abplanalp, W. T., <em>et al</em>. (2020) Efficiency and Target Derepression of Anti-miR-92a: Results of a First in Human Study. <em>Nucleic Acid Therapeutics</em>. <span style="color: #ff6600;"><a style="color: #ff6600;" href="https://doi.org/10.1089/nat.2020.0871" target="_blank" rel="noopener noreferrer">doi.org/10.1089/nat.2020.0871</a>.</span>

</div>